FDA Brief

Warning letters Drugs

FDA warning letter to

Biomic Sciences, LLC dba ION Intelligence of Nature

High riskIssued May 9, 2024Posted May 28, 2024Division of Human and Animal Food Operations East II

Biomic Sciences' nasal spray was grossly contaminated with microorganisms, and FDA also found manufacturing and labeling violations.

What happened

After an inspection from June 12 through August 31, 2023, and a website review, FDA lab testing found gross microbial contamination in ION Intelligence of Nature Sinus Support Nasal Spray lot 2302081HGA. FDA also cited violations of current good manufacturing practice (CGMP) for drugs and dietary supplements and low-acid canned food registration/process filing failures. The company recalled all lots of the nasal spray and related sinus sprays to the consumer level.

What FDA found

  1. FDA found gross microbial contamination in a lot of the nasal spray, and the firm released drug product without testing each batch for objectionable microorganisms.

    21 CFR 211.165(b); 21 U.S.C. 351(a)(1)
  2. The quality control unit did not ensure drug products were made under CGMP and met identity, strength, quality, and purity specifications.

    21 CFR 211.22
  3. The firm did not register as a low-acid canned food processor or file a scheduled process for Ion Gut Support.

    21 CFR 108.35(c)(1)-(2); 21 CFR 113.83
  4. The firm lacked dietary supplement component specifications for identity, purity, and contamination limits.

    21 CFR 111.70(b)(1)-(3)
  5. The firm did not quarantine components before using them in Ion Gut Support.

    21 CFR 111.155(c)
  6. Ion Gut Support labels did not declare all ingredients and did not format the Supplement Facts panel as required.

    21 U.S.C. 343(i)(2), 343(q)(5)(F); 21 CFR 101.36

What FDA wants

FDA asks the firm to correct the cited violations, clarify whether it will resume making drug products at this facility for the U.S. market, and notify FDA before marketing such products. The provided letter does not state a response deadline.

Who should pay attention

  • companies making nasal sprays or other mucosal drug products
  • dietary supplement brands that rely on contract manufacturers
  • low-acid canned food processors and their quality teams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk